July 28, 2010
The National Community Pharmacists Association (NCPA) offered recommendations to the U.S. Food and Drug Administration (FDA) at a two-day public meeting that concluded today and was held to solicit input as the agency designs and implements Risk Evaluation and Mitigation Strategies (REMS) intended to promote drug safety.
"Pharmacists take seriously their role as the primary source of drug information for their patients," said NCPA Acting Executive Vice President Douglas Hoey, RPh. "Pharmacists provide both life-saving medications to their patients, as well as critical written and verbal drug information and counseling that allow medications to be used most appropriately and safely. Going forward, we urge the FDA to leverage the value that community pharmacists offer related to the proper use of medications and avoidance of costly mistakes down the road."
NCPA's Vice President for Policy and Regulatory Affairs, Ronna Hauser, PharmD, presented the following views and recommendations to the FDA:
NCPA's full statement to the FDA regarding REMS is available here. In addition, NCPA's statement to the FDA concerning a class-wide opioid REMS can be found here.
The National Community Pharmacists Association (NCPA®) represents America's community pharmacists, including the owners of more than 22,700 independent community pharmacies, pharmacy franchises, and chains. Together they represent an $88 billion health-care marketplace, employ over 65,000 pharmacists, and dispense over 40% of all retail prescriptions. To learn more go to www.ncpanet.org or read NCPA's blog, The Dose, at http://ncpanet.wordpress.com.
Senior Vice President, Public Affairs
Director, Public Relations
NCPA News Release FeedWhat is RSS?
NCPA Advocacy Center
Legislative Action Network
NCPA's Blog — The Dose,
eNews Weekly Archives
Business Plan Competition,
Programs & Awards,
© NCPA • 100 Daingerfield Road • Alexandria, VA 22314 • 703.683.8200 • 703.683.3619 fax • email@example.com
NCPA ID #